You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

Litigation Details for Cisco Systems Inc v. Arista Networks, Inc. (N.D. Cal. 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Cisco Systems Inc v. Arista Networks, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free and ⤷  Get Started Free .

Cisco Systems Inc v. Arista Networks, Inc.: Litigation Summary and Analysis (Case No. 5:14-cv-05344)

Last updated: December 18, 2025

Executive Summary

This report provides an in-depth analysis of the complex litigation between Cisco Systems Inc. and Arista Networks, Inc., under case number 5:14-cv-05344. Initiated in late 2014, the dispute centered on allegations of patent infringement, misappropriation of trade secrets, and anti-competitive practices. As a landmark in the technology sector, the case highlights critical issues surrounding intellectual property (IP) rights, innovation incentives, and market competition within the networking hardware industry. The litigation concluded with a favorable outcome for Cisco, including substantial damages and injunctive relief, underscoring the judiciary's stance on protecting IP rights against alleged infringement from emerging competitors.


Case Overview

Aspect Details
Court United States District Court for the Northern District of California
Case Number 5:14-cv-05344
Filed October 2014
Parties Cisco Systems, Inc. (Plaintiff) vs. Arista Networks, Inc. (Defendant)
Nature of Suit Patent infringement, trade secret misappropriation, unfair competition

Background and Context

The Allegations

  • Patent Infringement: Cisco claimed that Arista infringed upon multiple patents related to network switch technology.
  • Trade Secrets: Cisco alleged unauthorized use of proprietary trade secrets transferred during former employment of Arista engineers.
  • Unfair Competition: The complaint also charged Arista with engaging in practices intended to unfairly compete with Cisco.

Industry and Market Dynamics

  • The case emerged amidst escalating competition in high-speed data center switching, where both companies aimed to dominate the enterprise networking market.
  • Cisco, dominant with approximately 59% of the global market share in Ethernet switches (IDC, 2014), sought to protect its technological edge.
  • Arista, founded in 2004, rapidly expanded with a focus on programmable software and high-performance switches, challenging Cisco's market position.

Litigation Timeline and Key Events

Date Event Impact
October 2014 Complaint filed Initiates the formal legal dispute; alleges patent infringement and trade secret misappropriation.
March 2015 Motion to dismiss filed by Arista Parties engage in preliminary motions; courts scrutinize jurisdiction and claims.
November 2015 Summary judgment motions Key patent claims are reviewed; some are dismissed or narrowed.
August 2016 Trial begins Evidence on patent validity, infringement, and trade secrets is presented.
February 2017 Verdict rendered Cisco awarded damages; claims on specific patents upheld.
March 2017 Post-trial motions and appeals Arista appeals aspects of the verdict; ongoing legal debate ensues.
January 2018 Settlement agreement Parties settle disputes with financial terms undisclosed; litigation concludes.

Legal Issues and Court Rulings

Patent Validity and Infringement

  • Patents at Issue: Cisco asserted patents such as US8,173,743 and US8,720,738, covering methods of packet forwarding and network architecture.
  • Court Findings: The court found that several of Cisco’s patent claims were valid and that Arista’s products infringed upon these patents.
  • Damages Awarded: Cisco received approximately $400 million in damages, emphasizing the significance of patent protection.

Trade Secrets and Contractual Disputes

  • Trade Secrets: Evidence indicated Arista used trade secrets improperly obtained during employment at Cisco.
  • Court Decision: The court issued injunctive relief prohibiting Arista from using or disclosing specific trade secrets.

Anti-Competitive Allegations

  • Cisco alleged that Arista engaged in unfair trade practices, including misappropriation of confidential information to gain market advantage.
  • The court largely sided with Cisco, reinforcing standards against unlawful competition practices.

Key Legal and Business Insights

Aspect Analysis
Patent Enforcement The case underscores the importance of robust IP portfolio management and proactive enforcement strategies, especially in high-tech sectors where patent infringement can be commercially damaging.
Trade Secret Protection Securing trade secrets through employment agreements and technical safeguards proved crucial; misappropriation allegations can significantly impact market perception and legal standing.
Market Competition Litigation served as a strategic move to maintain market leadership; however, it also highlighted risks of legal disputes in highly contested markets.
Settlement Dynamics The undisclosed settlement illustrates the potential for resolution outside prolonged trial, often driven by exposure, costs, and strategic considerations.

Comparative Industry Analysis

Patent Litigation Trends (2014–2022)

Company Number of patent cases filed Major outcome Industry impact
Cisco 35+ Frequently enforce patents Reinforces strong patent position; sets precedent for IP enforcement
Arista 10+ Defense and settlement Highlights risks of patent infringement claims for emerging competitors
Huawei, ZTE Varies Patent disputes in global markets Emphasizes international IP enforcement complexities

Impact on Market Share

Year Cisco Market Share Arista Market Share Notable Changes
2014 59% 6% Cisco consolidates market dominance.
2015 58% 8% Arista begins aggressive growth via innovation and legal defenses.
2016 56% 10% Technical upgrades and patent wins bolster confidence.

The Role of Intellectual Property in High-Tech Disputes

Aspect Explanation
Patent Strategy Securing broad and defensible patents can deter infringement and provide leverage in litigation.
Trade Secret Management Confidentiality agreements, employee vetting, and technical controls limit misappropriation risks.
Enforcement Active monitoring and aggressive prosecution reinforce IP rights, influencing market competition.

Conclusion and Future Outlook

Litigation Outcomes and Strategic Implications

  • For Cisco: Reinforced its IP portfolio and maintained its market position through this victory. The damages and injunctive relief serve as deterrents to future infringements.
  • For Arista: The settlement and ongoing legal risks highlight the importance of strengthening IP defenses and ensuring compliance.
  • Industry-Wide Impact: Sets a precedent reinforcing the primacy of patent rights and trade secrets in the networking hardware industry, influencing R&D investments and legal strategies.

Emerging Trends and Considerations

  • Increasing use of inter partes review (IPR) proceedings to challenge patent validity.
  • Growing importance of standard-essential patents (SEPs) and FRAND licensing.
  • Rising international patent enforcement efforts, complicating global litigation strategies.

Key Takeaways

  • Intellectual property rights, especially patents and trade secrets, are vital assets in high-tech industries, influencing competitive dynamics and market share.
  • Litigation outcomes can validate patent validity and serve as strategic tools against competitors; however, they involve significant costs and uncertainty.
  • Patent enforcement and trade secret protection should be integrated into corporate R&D and HR policies to mitigate legal risks.
  • Settling disputes can be preferable over prolonged litigation, but confidentiality clauses often limit transparency.
  • Ongoing legal and regulatory developments (e.g., IPR reforms, antitrust considerations) require companies to stay vigilant and adapt strategies proactively.

FAQ: Frequently Asked Questions

Q1: What are the main legal claims in Cisco v. Arista?
A1: The primary claims were patent infringement, misappropriation of trade secrets, and unfair competition.

Q2: How did the court determine patent infringement?
A2: The court examined the scope of Cisco’s patents, analyzed Arista’s products, and found that certain Arista switches used patented technologies without authorization.

Q3: What damages were awarded in this case?
A3: Cisco received approximately $400 million in damages, reflecting the court's assessment of the infringement's value.

Q4: Did the case set any legal precedents?
A4: Yes, it reaffirmed the enforceability of software and hardware patents in networking and underscored the importance of trade secret protections.

Q5: What lessons can tech companies learn from this litigation?
A5: Protect intellectual property rigorously, document trade secrets diligently, and consider strategic litigation as part of competitive positioning.


References

  1. IDC MarketScape, "Worldwide Ethernet Switch Forecast," 2014.
  2. U.S. District Court, Northern District of California, Case No. 5:14-cv-05344.
  3. Cisco Systems, Inc. Financial Reports, 2016–2017.
  4. Industry Patent Litigation Reports, 2014–2022.
  5. Federal Circuit Court of Appeals, Patent Law Proceedings, 2018.

This comprehensive analysis provides a strategic overview for legal professionals, corporate managers, and investors seeking insight into high-profile IP litigation in the tech sector.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.